African Trypanosomiasis (Sleeping Sickness) Workup

  • Author: Randy O Odero; Chief Editor: Burke A Cunha, MD   more...
 
Updated: Jan 11, 2012
 

Laboratory Studies

  • General
    • In African trypanosomiasis (sleeping sickness), the most significant laboratory abnormalities include anemia, hypergammaglobulinemia, low complement levels, elevated erythrocyte sedimentation rate (ESR), thrombocytopenia, and hypoalbuminemia, but not eosinophilia or abnormal liver function.
    • In West African trypanosomiasis, the total immunoglobulin M (IgM) level is notably higher in blood and CSF (along with high CSF protein).
    • A definitive diagnosis of infection requires actual detection of trypanosomes in blood, lymph nodes, CSF, skin chancre aspirates, or bone marrow. However, symptomatic improvement after empiric treatment is the usual confirmatory test in areas where diagnostic studies are not readily available.
  • Lymph node aspiration at a high dry magnification (X400) is commonly used as a rapid test for trypanosomes. It requires immediate search for parasites because they are mobile for only 15-20 minutes. This test has more utility in T brucei gambiense trypanosomiasis.
  • Blood smear
    • A wet smear of unstained blood or Giemsa-stained thick smear (more sensitive) is used to evaluate for mobile trypanosomes, again for 15-20 minutes. Wright and Leishman stains are inadequate. This technique is most sensitive in early stages of disease, when the number of circulating parasites is highest (≥5000/mL), particularly in T brucei rhodesiense trypanosomiasis.
    • Better assays are now available, including the hematocrit centrifugation technique for buffy coat examination and the miniature anion-exchange centrifugation technique (mAECT), which filters out the red cells but not the trypanosomes. This test can be used to detect parasitemia levels as low as 5 parasites/mL; the test can be repeated on subsequent days to increase the yield when results are negative.
    • See the image below.African trypanosomiasis (sleeping sickness). HumanAfrican trypanosomiasis (sleeping sickness). Human trypanosomes blood smear.
  • Chancre aspirate can be used as a wet preparation, especially in East African trypanosomiasis, but a blood smear is more sensitive.
  • Bone marrow aspiration results may be positive in some patients.
  • CSF assay
    • Lumbar puncture should be performed whenever trypanosomiasis is suspected. CSF examination helps to diagnose and stage the disease. However, a negative result does not necessarily rule out the diagnosis.
    • The double centrifugation technique is the most sensitive method to detect the trypanosomes.
    • Other CSF findings include elevated WBC count, elevated IgM levels, elevated total protein levels, and raised intracranial pressure. An uncommon characteristic finding is Mott cells, which are thought to be large eosinophilic plasma cells containing IgM that have failed to secrete their antibodies.
    • Increased intrathecal synthesis of IgM has been found to be the most sensitive indicator of CNS involvement in African trypanosomiasis.
Next

Imaging Studies

  • CT scanning and MRI of the head: Both head CT scanning and MRI reveal cerebral edema and white matter enhancement, respectively, in patients with late-stage African trypanosomiasis.
  • EEG in neurologic involvement usually shows slow wave oscillations (delta waves), a nonspecific finding.
Previous
Next

Other Tests

  • General: Field serology-based diagnosis of African trypanosomiasis has been slow to progress over the past decades. Although many research tools are available for diagnosis, few are used clinically in endemic areas.
  • Serologic antibody detection
    • The standard serologic assay to diagnose West African trypanosomiasis is the card agglutination test for trypanosomiasis (CATT).
    • The CATT can be conducted in the field without electricity, and results are available in only 10 minutes. It is highly sensitive (96%) but less specific because of cross-reactivity with animal trypanosomes.
    • Commercial antibody tests for Eastern African trypanosomiasis are not available.
  • Antigen detection tests based on enzyme-linked immunosorbent assay (ELISA) technology have been developed. They have shown inconsistent results and are not yet commercially available.
  • Culture of CSF, blood, bone marrow aspirate, or tissue specimens can be performed in liquid media.
  • Other tests developed but not frequently used clinically include antibody detection in the CSF and intrathecal space (low sensitivity), polymerase chain reaction (PCR), and serum proteomic tests.
  • Research tools such as isoenzyme analysis and restriction fragment length polymorphism (RFLP) are used for definitive subspecies identification.
Previous
Next

Procedures

  • Lumbar puncture: CSF fluid is used to detect trypanosomes and to measure WBC counts, protein, and IgM in patients with parasitemia or positive serologies or symptoms. Importantly, CNS disease can manifest early in East African trypanosomiasis.
Previous
Proceed to Treatment & Management
 
 
Contributor Information and Disclosures
Author

Randy O Odero  MB, ChB, Attending Physician, Infectious Diseases

Randy O Odero is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Coauthor(s)

Kerry O Cleveland, MD  Associate Professor of Medicine, University of Tennessee College of Medicine; Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Methodist Healthcare of Memphis

Kerry O Cleveland, MD is a member of the following medical societies: American College of Physicians, Infectious Diseases Society of America, and Society for Healthcare Epidemiology of America

Disclosure: Nothing to disclose.

Kitonga P Kiminyo, MD  Consulting Staff, ID Consultants Inc

Kitonga P Kiminyo, MD is a member of the following medical societies: Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Daniel R Lucey, MD, MPH  Chief, Fellowship Program Director, Department of Internal Medicine, Division of Infectious Diseases, Washington Hospital Center; Professor, Department of Internal Medicine, Uniformed Services University of the Health Sciences

Daniel R Lucey, MD, MPH is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

Specialty Editor Board

Gary L Gorby, MD  Associate Professor, Departments of Internal Medicine and Medical Microbiology and Immunology, Division of Infectious Diseases, Creighton University School of Medicine; Associate Professor of Medicine, University of Nebraska Medical Center; Associate Chair, Omaha Veterans Affairs Medical Center

Gary L Gorby, MD is a member of the following medical societies: Alpha Omega Alpha, American Medical Association, American Society for Microbiology, Infectious Diseases Society of America, and New York Academy of Sciences

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Joseph F John Jr, MD, FACP, FIDSA, FSHEA  Clinical Professor of Medicine, Molecular Genetics and Microbiology, Medical University of South Carolina College of Medicine; Associate Chief of Staff for Education, Ralph H Johnson Veterans Affairs Medical Center

Disclosure: Nothing to disclose.

Eleftherios Mylonakis, MD  Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital

Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD  Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America

Disclosure: Nothing to disclose.

References

  1. Truc P, Lando A, Penchenier L, Vatunga G, Josenando T. Human African trypanosomiasis in Angola: clinical observations, treatment, and use of PCR for stage determination of early stage of the disease. Trans R Soc Trop Med Hyg. Jan 2012;106(1):10-4. [Medline].

  2. Simarro PP, Cecchi G, Franco JR, Paone M, Fèvre EM, Diarra A, et al. Risk for human african trypanosomiasis, central Africa, 2000-2009. Emerg Infect Dis. Dec 2011;17(12):2322-4. [Medline].

  3. Kohagne TL, M'eyi MP, Kamkuimo RG, Kaba D, Louis JF, Mimpfoundi R. Transmission of human African trypanosomiasis in the Komo-Mondah focus, Gabon. Pan Afr Med J. 2011;8:36. [Medline]. [Full Text].

  4. Abramowicz M. Drugs For Parasitic Infections. In: Abramowicz M, ed. The Medical Letter on Drugs and Therapeutics. New Rochelle, NY: The Medical Letter, Inc; 2000:1-12.

  5. [Best Evidence] Bisser S, N'Siesi FX, Lejon V, Preux PM, Van Nieuwenhove S, Miaka Mia Bilenge C, et al. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J Infect Dis. Feb 1 2007;195(3):322-9. [Medline].

  6. Priotto G, Kasparian S, Ngouama D, Ghorashian S, Arnold U, Ghabri S, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis. Dec 1 2007;45(11):1435-42. [Medline].

  7. Barrett MP. The fall and rise of sleeping sickness. Lancet. Apr 3 1999;353(9159):1113-4. [Medline].

  8. Brun R, Balmer O. New developments in human African trypanosomiasis. Curr Opin Infect Dis. Oct 2006;19(5):415-20. [Medline].

  9. Centers for Disease Control and Prevention. Trypanosomiasis Fact Sheet. CDC. May, 2000;[Full Text].

  10. Chappuis F, Loutan L, Simarro P, Lejon V, Büscher P. Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev. Jan 2005;18(1):133-46. [Medline].

  11. Drugs for Parasitic Infections. Medical Lett Drugs Ther. August/2004.

  12. Hide G. History of sleeping sickness in East Africa. Clin Microbiol Rev. Jan 1999;12(1):112-25. [Medline].

  13. Kozarsky PE, Arguin PM, Navin AW. African Trypanosomiasis (African Sleeping Sickness). Travelers' Health: Yellow Book. Health Information for International Travel, 20. 2005-2006;[Full Text].

  14. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. Jul-Aug 1999;93(4):439-42. [Medline].

  15. Lejon V, Büscher P. Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health. May 2005;10(5):395-403. [Medline].

  16. Micromedex. Antiparasitic drug information. Micromedex electronic database. May, 2000.

  17. Pepin J. African Trypanosomiasis. In: Strickland GT, ed. Hunter's Tropical Medicine. 7th ed. Philadelphia, Pa: WB Saunders; 1998:643-53.

  18. Pepin J, Milord F, Guern C. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet. Jun 3 1989;1(8649):1246-50. [Medline].

  19. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, Manthelot CR, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis. Jun 1 2005;191(11):1922-31. [Medline].

  20. Sinha A, Grace C, Alston WK. African trypanosomiasis in two travelers from the United States. Clin Infect Dis. Oct 1999;29(4):840-4. [Medline].

  21. Smith DH, Pepin J, Stich AH. Human African trypanosomiasis: an emerging public health crisis. Br Med Bull. 1998;54(2):341-55. [Medline].

  22. Turner CM. Antigenic variation in Trypanosoma brucei infections: an holistic view. J Cell Sci. Oct 1999;112 (Pt 19):3187-92. [Medline].

  23. World Health Organization. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1998;881:I-VI, 1-114. [Medline].

  24. World Health Organization. WHO fact sheet on African Trypanosomiasis. WHO fact sheets. Revised August 2006;Fact sheet 259:[Full Text].

 
Previous
Next
 
African trypanosomiasis (sleeping sickness). Human trypanosomes blood smear.
Table 1. Medications Recommended for Treatment of African Trypanosomiasis
Type of TrypanosomiasisMedications



Stage 1



(Hemolymphatic Stage)



Medications



Stage 2



(Neurologic [CNS] Stage)



East African trypanosomiasis (caused by T brucei rhodesiense)Suramin 100-200 mg IV test dose, then 1 g IV on days 1, 3, 7, 14, 21Melarsoprol 2-3.6 mg/kg/d IV for 3 d; after 1 wk, 3.6 mg/kg/d for 3 d; after 10-21 d, repeat the cycle
West African trypanosomiasis (caused by T brucei gambiense)Pentamidine isethionate 4 mg/kg/d IM for 10 d



or



Suramin 100-200 mg IV test dose, then 1 g IV on days 1, 3, 7, 14, 21



Melarsoprol 2-3.6 mg/kg/d IV for 3 d; after 1 wk, 3.6 mg/kg/d for 3 days; after 10-21 d, repeat the cycle



or



Eflornithine 400 mg/kg/d IV in 4 divided doses for 14 d



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.